Relapsed Acute Myelogenous Leukemia (AML) (DBCOND0069493)

Identifiers

Synonyms

Acute Myeloid Leukemia, in Relapse / Acute, relapsed Myeloid Leukemia / Relapsed AML / Relapsed Acute Myeloid Leukemia (AML) / Relapsed Acute Myeloid Leukemia / Relapsed Acute Myelogenous Leukemia / Acute, relapsed Myelogenous Leukemia / Acute Myeloid Leukemia (AML) Relapse / Acute Myelogenous Leukemia in Relapse / Myeloid Leukemia in Relapse (Disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Enasidenib	An isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.	Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Isocitrate dehydrogenase [NADP], mitochondrialtarget Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2D6enzyme Cytochrome P450 3A4enzyme UDP-glucuronosyltransferase 1A1enzyme UDP-glucuronosyltransferase 1A3enzyme UDP-glucuronosyltransferase 1A4enzyme UDP-glucuronosyltransferase 1A9enzyme UDP-glucuronosyltransferase 2B7enzyme UDP-glucuronosyltransferase 2B15enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 6transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier family 22 member 2transporter Solute carrier organic anion transporter family member 1B3transporter Organic anion transporter 3transporter Albumincarrier Isocitrate dehydrogenase [NADP] cytoplasmictarget Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrialtarget Isocitrate dehydrogenase [NAD] subunit beta, mitochondrialtarget Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrialtarget
Gemtuzumab ozogamicin	A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.	Myeloid cell surface antigen CD33target Low affinity immunoglobulin gamma Fc region receptor III-Btarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget High affinity immunoglobulin gamma Fc receptor Itarget
Gilteritinib	An AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia.	Albumincarrier Cytochrome P450 3A4enzyme Receptor-type tyrosine-protein kinase FLT3target Serotonin Receptorstarget ATP-dependent translocase ABCB1transporter Multidrug and toxin extrusion protein 1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 1transporter Tyrosine-protein kinase receptor UFOtarget ALK tyrosine kinase receptortarget
Ivosidenib	An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation.	Isocitrate dehydrogenase [NADP] cytoplasmictarget Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C8enzyme Organic anion transporter 3transporter ATP-dependent translocase ABCB1transporter
Olutasidenib	An isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.	Isocitrate dehydrogenase [NADP] cytoplasmictarget Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Organic anion transporter 3transporter Solute carrier family 22 member 2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Cytochrome P450 2B6enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06552416	Safety of MT-401-OTS in Patients With Relapsed AML or MDS	MT-401	treatment	1	not_yet_recruiting
NCT06017258	A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia	No drug interventions	treatment	1	recruiting
NCT02267863	A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS	APTO-253	treatment	1	terminated
NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	Cyclophosphamide Fludarabine	treatment	1	active_not_recruiting
NCT04898894	Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia	Cytarabine Filgrastim Fludarabine Hydrocortisone Methotrexate Selinexor Venetoclax	treatment	1	recruiting
NCT02768792	High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML	Pembrolizumab	treatment	2	active_not_recruiting
NCT06128044	CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT05317403	Venetoclax to Augment Epigenetic Modification and Chemotherapy	Cytarabine Filgrastim Fludarabine Venetoclax Vorinostat	treatment	1	recruiting
NCT02353143	Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	1	terminated
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Devimistat Metformin	treatment	2	not_yet_recruiting
NCT06532084	Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen	Sorafenib	treatment	2	recruiting
NCT05546580	Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)	Gilteritinib ORY-1001	treatment	1	recruiting
NCT04678336	CD123 Redirected T Cells for AML in Pediatric Subjects	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT06372717	A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS	Azacitidine	treatment	1 / 2	recruiting
NCT02204085	A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Decitabine GO-203-2C	treatment	1 / 2	active_not_recruiting
NCT06459024	Master Framework For Relapse or Refractory Acute Myeloid Leukemia	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT05735184	A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML	Azacitidine Cytarabine Daunorubicin Venetoclax Ziftomenib	treatment	1	recruiting
NCT05949125	Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123	No drug interventions	treatment	1	recruiting
NCT04914845	KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	Padnarsertib	treatment	1	recruiting
NCT05105152	PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML	No drug interventions	treatment	1	recruiting
NCT06281847	An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT06201247	Off-the-shelf CD123 CAR-NK for R/R AML	No drug interventions	treatment	0	recruiting
NCT05597306	Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Bomedemstat IMG-7289 Venetoclax	treatment	1	recruiting
NCT06125652	Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)	No drug interventions	treatment	1 / 2	recruiting
NCT03690154	A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML	FN-1501	treatment	1	terminated
NCT04716452	Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	No drug interventions	treatment	1	not_yet_recruiting
NCT05211570	AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia	AB-8939 Azacitidine	treatment	1 / 2	recruiting
NCT04402541	Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome	No drug interventions	treatment	1	completed
NCT05190471	A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)	Decitabine	treatment	1	recruiting
NCT03957915	Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia	No drug interventions	treatment	0	recruiting
NCT05587088	Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT05506332	Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia	Mercaptopurine Venetoclax	treatment	1	recruiting
NCT05488132	Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)	No drug interventions	treatment	1 / 2	recruiting
NCT05124288	Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways	No drug interventions	Not Available	Not Available	recruiting
NCT04867928	Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia	Azacitidine Venetoclax	treatment	2	recruiting
NCT04321161	Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment	Sodium bicarbonate	treatment	0	completed
NCT03053206	A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia	No drug interventions	treatment	2	unknown_status
NCT02438761	PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)	Gedatolisib	treatment	2	terminated
NCT03116477	Study Investigating the Efficacy of the Addition of Crenolanib to Chemotherapy vs Chemotherapy Alone in Patients With R/R FLT3 Mutated AML	Crenolanib Cytarabine Filgrastim Fludarabine Idarubicin Mitoxantrone	treatment	3	not_yet_recruiting
NCT05226468	An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia	No drug interventions	treatment	1	active_not_recruiting
NCT03560908	Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation	Dasatinib	treatment	1	withdrawn
NCT03516760	Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia	No drug interventions	treatment	1	terminated
NCT02675478	Phase 1 Study of Quizartinib	Quizartinib	treatment	1	completed
NCT02091245	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	Selinexor	treatment	1	active_not_recruiting
NCT03207191	Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation	BI-836858	treatment	1	completed
NCT03081780	Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML	No drug interventions	treatment	1	completed
NCT01743807	Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia	No drug interventions	treatment	1	terminated
NCT00939653	T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)	Clofarabine Cyclophosphamide Cytarabine Etoposide Filgrastim	treatment	2	terminated
NCT04354025	Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML	Cytarabine Filgrastim Fludarabine Human interleukin-2 Natural Killer Cell	treatment	2	withdrawn
NCT04891757	FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies	Cytarabine Decitabine	treatment	1	recruiting
NCT01961765	Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cabozantinib	treatment	1	completed
NCT02996474	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia	Decitabine Pembrolizumab	treatment	1 / 2	completed
NCT02109627	Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML	Cytarabine Ficlatuzumab	treatment	1	terminated
NCT06177067	Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia	Azacitidine Cytarabine Hydrocortisone Methotrexate Revumenib Venetoclax	treatment	1	recruiting
NCT04678401	IS-free Treg HaploHCT	Coenzyme M Cyclophosphamide Fludarabine Thiotepa	treatment	1	recruiting
NCT04582864	Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)	Flotetuzumab	treatment	2	terminated
NCT06561152	Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML	Cladribine Cytarabine Tagraxofusp	treatment	1 / 2	not_yet_recruiting
NCT05028751	A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)	Gilteritinib Lanraplenib	treatment	1 / 2	terminated
NCT06536959	VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS	Azacitidine Decitabine Tislelizumab Venetoclax	treatment	2	recruiting
NCT04797767	Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms	Cladribine Cytarabine Filgrastim Mitoxantrone Venetoclax	treatment	1	suspended
NCT05456048	Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML	No drug interventions	Not Available	Not Available	completed
NCT05362942	Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia	Azacitidine Cytarabine Decitabine Venetoclax	treatment	2	not_yet_recruiting
NCT04893915	Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS	Cyclophosphamide Fludarabine Human interleukin-2	treatment	2	withdrawn
NCT03787498	A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	No drug interventions	treatment	1	completed